Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Research

Pharmaceutical

Science

Biotechnology

Pharmaceutical, Conference

More Like This

Business Wire associated0

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

PR Newswire associated0

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting

Fermion's TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026

Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

PR Newswire associated0

Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting